Clinical trial NCT05138835: BOTOX® Cosmetic and Skin Health.
Official title: A Randomized, Double Blind Evaluation of the Effects of BOTOX® Cosmetic on Skin Health
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oily Skin
Lead sponsor: Erevna Innovations Inc.
Sponsor class: OTHER
First posted: 2021-12-01
Enrollment: 34
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a two cohort, randomized, double blind, single center study to evaluate the effects of Botox Cosmetic (BTX) on sebum protection. Thirty-four female subjects with moderate-to-high skin sebum concentration will be recruited and randomized in a 1:1 ratio to treatment groups.


Eligibility criteria: Inclusion Criteria:

1. Age above 18 years.
2. Female sex.
3. A SebumeterTM score \>66ug/cm2 at Baseline.
4. Ability to adequately understand the verbal explanations and the written subject information provided in local language and ability and willingness to give consent to participate in the study.
5. Signed and dated informed consent to participate in the study and unrestricted use of facial images for marketing purpose.
6. If female of childbearing potential: a negative urine pregnancy test before all treatments is required.
7. Subject agrees to use the same topical cosmetic products (e.g., cleansers, moisturizers) throughout the duration of the trial, and at least for 30 days prior to enrolment.
8. Subject is on a stable diet and is not planning any major dietary changes throughout the duration of the trial.
9. Subject is not planning on undergoing any major hormonal changes throughout the duration of the study (e.g., menopause, change in medications).

Exclusion Criteria:

1. Current Pregnancy or lactation \[sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)\];
2. Patients meeting any official BOTOX® Cosmetic contra-indications;
3. Inability to comply with follow-up and abstain from other treatments in the region of interest during the study period;
4. Heavy smokers, classified as smoking more than 12 cigarettes per day;
5. History of severe or multiple allergies manifested by anaphylaxis;
6. Previous tissue revitalization therapy in the treatment area within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion;
7. Previous treatment with neurotoxins in the area under assessment, within 6 months prior to enrolment;
8. Previous treatment with soft tissue fillers in the area under assessment, within 6 months prior to enrolment;
9. Subjects presenting with known allergy to BOTOX® Cosmetic.
10. Subjects presenting with porphyria.
11. Subjects with active disease, such as inflammation, infection or tumors, in or near the intended treatment site.
12. History of bleeding disorders or treatment with thrombolytics, anticoagulants, or inhibitors of platelet aggregation (e.g. Aspirin or other non-steroid anti-inflammatory drugs \[NSAIDs\]), within 2 weeks before treatment.
13. Subjects using immunosuppressants.
14. Subjects prescribed systematic or topical (in the area under assessment) antibiotics within 1 month of enrolment.
15. Tattoos, piercings or visible markings that in the treating investigator's opinion, may interfere with results or assessments.
16. Cancer or precancer in the treatment area, e.g. actinic keratosis.
17. Patients with a tendency to form hypertrophic scars or any other healing disorders.

Primary outcomes:
measure: Skin quality assessment
timeFrame: Baseline versus Week 4
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Erevna Innovations Inc
state: Quebec
Study officials:
affiliation: Erevna Innovations Inc.
name: Andreas Nikolis
role: PRINCIPAL_INVESTIGATOR
References: